根据提交给美国证券交易委员会（SEC）的文件披露，Viridian Therapeutics, Inc. 已与药明生物达成协议，后者将为其生产并供应在研药物Veligrotug。
此项合作标志着Viridian在推进其核心管线产品Veligrotug的开发和未来商业化进程中，迈出了关键一步。通过携手全球领先的合同研究、开发与生产组织（CRDMO）药明生物，Viridian旨在确保其候选药物能够获得高质量、可扩展的生产能力支持。
Veligrotug是Viridian公司管线中一款备受关注的候选疗法。此次生产供应协议的落实，不仅为其后续的临床试验提供了坚实的物质保障，也为潜在的商业化上市铺平了道路。对于生物科技公司而言，与具备国际水准的合作伙伴锁定产能，是降低研发风险、加速产品进程的重要战略举措。
该份SEC文件的披露，向市场传达了Viridian在推进业务运营方面的具体进展。投资者通常会密切关注此类涉及核心产品供应链建设的合作，将其视为评估公司执行力和未来发展潜力的重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.